Literature DB >> 15890156

Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment.

Soledad Gallego Melcón1, José Sánchez de Toledo Codina.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15890156     DOI： 10.1007/bf02710026

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  31 in total

Review 1.  Molecular genetics and pathogenesis of rhabdomyosarcoma.

Authors:  F G Barr
Journal:  J Pediatr Hematol Oncol       Date:  1997 Nov-Dec       Impact factor: 1.289

Review 2.  Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Authors:  R B Raney; J R Anderson; F G Barr; S S Donaldson; A S Pappo; S J Qualman; E S Wiener; H M Maurer; W M Crist
Journal:  J Pediatr Hematol Oncol       Date:  2001-05       Impact factor: 1.289

3.  Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.

Authors:  W Lawrence; J R Anderson; E A Gehan; H Maurer
Journal:  Cancer       Date:  1997-09-15       Impact factor: 6.860

4.  Cancer in the families of children with soft tissue sarcoma.

Authors:  J M Birch; A L Hartley; V Blair; A M Kelsey; M Harris; M D Teare; P H Jones
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

Review 5.  Multiple roles of the tumor suppressor p53.

Authors:  Jill Bargonetti; James J Manfredi
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

Review 6.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.

Authors:  F G Barr
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

7.  Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study.

Authors:  F H Kung; C B Pratt; R A Vega; N Jaffe; D Strother; M Schwenn; R Nitschke; A C Homans; C T Holbrook; B Golembe
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

8.  Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study.

Authors:  W A Newton; E A Gehan; B L Webber; H B Marsden; A J van Unnik; A B Hamoudi; M G Tsokos; H Shimada; D Harms; D Schmidt
Journal:  Cancer       Date:  1995-09-15       Impact factor: 6.860

9.  Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development.

Authors:  M E Horowitz; E Etcubanas; M L Christensen; J A Houghton; S L George; A A Green; P J Houghton
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

10.  Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma.

Authors:  W E Loh; H J Scrable; E Livanos; M J Arboleda; W K Cavenee; M Oshimura; B E Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.